The price is accelerating after sales forecasts for Q4 were raised.
Clear compression with a retest of the previous low, the price is now heading toward the blue resistance around $170, and in case of a breakout, could continue toward $208.
The medical sector has been largely overlooked in recent years in favor of AI stocks, but a renewed interest in 2026 is very likely.
Clear compression with a retest of the previous low, the price is now heading toward the blue resistance around $170, and in case of a breakout, could continue toward $208.
The medical sector has been largely overlooked in recent years in favor of AI stocks, but a renewed interest in 2026 is very likely.
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como asesoramiento o recomendaciones financieras, de inversión, de trading o de otro tipo proporcionadas o respaldadas por TradingView. Más información en Condiciones de uso.
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como asesoramiento o recomendaciones financieras, de inversión, de trading o de otro tipo proporcionadas o respaldadas por TradingView. Más información en Condiciones de uso.
